Trajectories of bone remodeling markers and bone mineral density during treatment with strontium ranelate in postmenopausal women previously treated with bisphosphonates

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 7, Issue , 2014, Pages 7-11

  Lima, Helisane ^a   Maia, Juliana ^a   Bandeira, Francisco ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Bisphosphonates; CTX; Osteocalcin; Osteoporosis; Strontium ranelate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; STRONTIUM RANELATE; VITAMIN D;

AGED; ARTICLE; BEDTIME DOSAGE; BONE DENSITY; BONE REMODELING; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MORNING DOSAGE; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

EID: 84899746259     PISSN: None     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMEDed.Ss15086     Document Type: Article

References (27)

1. Compston JE, Watts NB. Combination therapy for postmenopausal osteoporosis. Clin Endocrinol (Oxf). 2002; 56: 565-569.
2. Compston JE. The use of combination therapy in treatment of postmenopausal osteoporosis. Endocrine. 2012; 41: 11-18.
3. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013; 24: 23-57.
4. Blake GM, Compston JE, Fogelman I. Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J Bone Miner Res. 2009; 24: 1354-1357.
5. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis-where do we go from here? N Engl J Med. 2012; 366(22): 2048-2051.
6. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90: 2816-2822.
7. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004; 350: 459-468.
8. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in estabilished postmenopausal vertebral osteoporosis-a two-year randomized placebo controlled trial. J Clin Endocrinol Metab. 2002; 87: 2060-2066.
9. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int. 2001; 69: 121-129.
10. Arlot ME, Jiang Y, Genant HK, et al. Histomorphometric and microTC analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res. 2008; 23: 215-222.
11. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res. 2004; 19: 2012-2020.
12. Boivin G, Meunier PJ. Bone strontium distribuition and degree of mineralisation of bone after 2 and 3 years of treatment with strontium ranelate in postmenopausal women. Calcif Tissue Int. 2006; 78: 536.
13. Boivin G, Khebbab MT, Jaurand X, Farlay D, Meunier PJ, Delmas PD. Localization of strontium, by X-ray microanalysis cartography, in bone biopsies of postmenopausal osteoporotic women treated for 3 years with strontium ranelate. Calcif Tissue Int. 2007; 80: S118.
14. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized two-year, double-masked, dose ranging, placebo-controlled PREVOS study. Osteoporos Int. 2002; 13: 925-931.
15. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296(24): 2927-2938.
16. Bone HG, Hosking D, Devogelaer JP, et al. Ten's years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350: 1189-1199.
17. Sousa IO, Diniz ET, Marques TF, Griz L, Coutinho Mde A, Bandeira F. Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates. Arq Bras Endocrinol Metabol. 2010; 54(2): 244-249.
18. Li C, Paris O, Siegel S, et al. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment. J Bone Miner Res. 2010; 25(5): 968-975.
19. Boivin G, Farlay D, Khebbab MT, Jaurand X, Delmas PD, Meunier PJ. In osteoporotic women treated with strontiu ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. Osteoporos Int. 2010; 21(4): 667-677.
20. Fonseca JE. Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength. Rheumatology (Oxford). 2008; 47(suppl 4): iv17-iv19.
21. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008; 23: 1591-1600.
22. Meunier PJ, Boivin G, Marie PJ. About the comparison of two anabolic agentes, teriparatide and strontium ranelate, in treated osteoporotic women. J Bone Miner Res. 2009; 24(12): 2066.
23. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004; 19(5): 745-751.
24. Bruyère O, Collette J, Rizzoli R, et al. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int. 2010; 21(6): 1031-1036.
25. Middleton ET, Steel SA, Aye M, Doherty SM. The effect of prior bisphoshonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J Bone Miner Res. 2010; 25(3): 455-462.
26. Middleton ET, Steel SA, Aye M, Doherty SM. The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years. Osteoporos Int. 2012; 23: 295-303.
27. Busse B, Jobke B, Hahn M, et al. Effects of strontium ranalate administration on bisphosphonate-altered hydroxyapatite: matrix incorporation of strontium is accompanied by changes in mineralization and microstructure. Acta Biomater. 2010; 6(12): 4513-21.